Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

OptimizeRx (OPRX) Consolidated Net Income: 2010-2025

Historic Consolidated Net Income for OptimizeRx (OPRX) over the last 16 years, with Q3 2025 value amounting to $779000.0.

  • OptimizeRx's Consolidated Net Income rose 10853.79% to $779000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $4.8 million, marking a year-over-year increase of 11520.25%. This contributed to the annual value of -$15.3 million for FY2024, which is 1282.02% up from last year.
  • As of Q3 2025, OptimizeRx's Consolidated Net Income stood at $779000.0, which was up 10853.79% from $1.5 million recorded in Q2 2025.
  • In the past 5 years, OptimizeRx's Consolidated Net Income registered a high of $4.7 million during Q4 2024, and its lowest value of -$11.7 million during Q4 2023.
  • Moreover, its 5-year median value for Consolidated Net Income was -$2.9 million (2023), whereas its average is -$2.7 million.
  • As far as peak fluctuations go, OptimizeRx's Consolidated Net Income crashed by 879000.85% in 2022, and later soared by 14018.74% in 2024.
  • OptimizeRx's Consolidated Net Income (Quarter) stood at $623462.0 in 2021, then tumbled by 152.26% to -$325836.0 in 2022, then plummeted by 3503.04% to -$11.7 million in 2023, then surged by 140.19% to $4.7 million in 2024, then tumbled by 83.49% to $779000.0 in 2025.
  • Its Consolidated Net Income stands at $779000.0 for Q3 2025, versus $1.5 million for Q2 2025 and -$2.2 million for Q1 2025.